Status:
COMPLETED
Neurodynamics of Prosocial Emotional Processing Following Serotonergic Stimulation With N,N-Dimethyltryptamine (DMT) and Harmine in Healthy Subjects
Lead Sponsor:
Psychiatric University Hospital, Zurich
Collaborating Sponsors:
University of Basel
Conditions:
Emotions
Mood
Eligibility:
MALE
20-40 years
Phase:
EARLY_PHASE1
Brief Summary
The aim of the project is to assess brain network dynamics, self-referential information processing and prosociality and learning following the modulation of the serotonin-system by serotonergic-psych...
Eligibility Criteria
Inclusion
- Willing and capable to give informed consent for the participation in the study after it has been thoroughly explained
- Little or no previous experiences with psychedelic substances
- Body mass index (BMI) between 18.5 and 25
- Willing to refrain from drinking caffeine 3 days and alcohol the day before testing session, from drinking alcohol and caffeinated drinks at the testing days and from consuming psychoactive substances or other medications for 2 weeks before testing days and for the duration of the study
- Able and willing to comply with all study requirements
- Informed consent form was signed
- Good knowledge of the German language
Exclusion
- Previous significant adverse response to a hallucinogenic drug
- Participation in another study where pharmaceutical compounds will be given
- Self or first-degree relatives with present or antecedent psychiatric disorders
- History of head trauma or fainting
- Recent cardiac or brain surgery
- Current use of medication or psychotropic substances (including nicotine addiction)
- Presence of major internal or neurological disorders (including sepsis, pheochromocytoma, thyrotoxicosis, drug-induced fibrosis, familiar or basilar artery migraine)
- Cardiovascular disease (hypertonia, coronary artery disease, heart insufficiency, myocardial infarction, coronary spastic angina)
- Peripheral vascular disease (thromboangiitis obliterans, luetic arteritis, severe arteriosclerosis, thrombophlebitis, Raynaud's disease)
- Liver or renal disease
Key Trial Info
Start Date :
December 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 10 2022
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT04716335
Start Date
December 1 2020
End Date
January 10 2022
Last Update
October 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Psychiatric University Hospital
Zurich, Switzerland, 8032